Fibrosis Improvement with Pegozafermin Treatment in MASH Patients with F4 Fibrosis
R. Loomba, A. J. Sanyal, K.V. Kowdley, N. Alkhouri, P. Bedossa, S.A. Harrison, M. Gottwald, S. Feng, G.D. Agollah, C.L. Hartsfield, H. Mansbach, M. Margalit, M.F. Abdelmalek. Presented at The Liver Meeting AASLD, November 10-14, 2023.
BIO89-100, a Novel Glycopegylated FGF21 Analogue, Demonstrates Robust Reduction in Serum Lipids and Long Half-life in a Phase 1 Randomized, Controlled Single Ascending Dose Trial in Healthy Subjects
R. Loomba, H. Mansbach, L. Tseng, C. Chen, M. Rosenstock, G. Atiee and M. Margalit. Poster presented at the American Association for the Study of Liver Diseases (AASLD) Meeting, November 8-12, 2019 (Boston, MA).
Weekly Subcutaneous Administration of BIO89-100, a Novel GlycoPEGylated-Fibroblast Growth Factor21 (FGF21) Analogue, Inhibits Sweetness Preference in Obese Cynomolgus Monkeys
M. Rosenstock, Y. Liu, H. Mansbach and M. Margalit. Poster presented at the American Association for the Study of Liver Diseases (AASLD) Meeting, November 8-12, 2019 (Boston, MA).
